Soon-Shiong, Patrick,Niazi, Kayvan,Sieling, Peter,Lazar, Adam
申请号：
AU2018244221
公开号：
AU2018244221A1
申请日:
2018.03.26
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Contemplated treatment compositions and methods are directed to co-administration of sensitized genetically modified NK cells and recombinant IL-12, wherein the genetically modified NK cells were preferably sensitized by constitutive exposure to IL-2 and wherein the IL-12 is expressed from a recombinant virus or given as an IL-12-antibody conjugate. Such treatment increases IFNγ secretion by the sensitized NK cells, and advantageously also increases expression of NKG2D.
